Description

“BLEs is a pulmonary surfactant for use in the treatment of premature infants suffering from Neonatal Respiratory Distress Syndrome.

BLEs is unique; there is no generic form of this product. BLES Biochemicals Inc. is a privately owned Canadian controlled pharmaceuticals company.
Summary Product Information

• Route of administration: Intratracheal instillation
• Dosage Form/Strength: Suspension / 27mg phospholipid/mL

Description
BLEs (Bovine Lipid Extract surfactant) is extracted from bovine lung surfactant. The manufacturing process removes hydrophilic  proteins, the majority of which would be surfactant associated proteins SP-A, and selects for hydrophobic phospholipids and surfactant-associated proteins SP-B and SP-C.
“BLEs can rapidly affect oxygenated and lung compliance.”